It was shown that glioma patients with a methylated MGMT gene had a better survival rate when treated with the alkylating agent temozolomide or other alkylating agents when compared to patients with an unmethylated promoter presumably because of increased cell killing by the chemotherapy agent [55]. The gene discussed is MGMT; the disease is central nervous system cancer.